EGFR and non-small cell lung carcinoma: The use of third generation tyrosine kinase inhibitor (TKI) osimertinib, is currently approved as first line of treatment for patients with advanced non-small cell lung cancer (NSCLC) harbouring both activating and T790M mutation of epidermal growth factor receptor (EGFR) and a great clinical benefit was observed1,2.